Home Drug pricing

Keyword: Drug pricing

17 results found

Amid the increasing introduction of specialized medicines in Canada, key stakeholders in the private payer health-care sector are enhancing their collaborations to maintain the value of private drug coverage, said Joe Farago, executive director of private payers and investment at Innovative Medicines Canada, during a webinar by the Group Insurance Pharmaceutical Committee this week. “[The […]

Copyright_Aleksandr Kalugin_123RF

Imagine that a few pills a day could transform an employee’s life — that they could get back to work, perform better, have fewer sick days, be more present and avoid continuously deteriorating health. Now, what if this life-changing medicine is for a rare disease that isn’t covered under the employee’s benefits plan because of […]

Total drug costs grew to $2 billion in 2021, rising steadily from $1.4 billion in 2017, according to Green Shield Canada’s annual drug trends report. The report, which is based on claims reported by Green Shield Canada, found the number of claimants also increased from 1.9 million to 2.1 million over the same period. While […]

  • By: Staff
  • September 23, 2022 September 22, 2022
  • 09:00

The amendments to the Patented Medicine Prices Review Board regulations are officially taking effect July 1, after being delayed multiple times. The changes, which were originally proposed in 2019, are the first significant update to the regulations in more than 30 years. After consulting with stakeholders, Health Canada will be moving forward with the implementation of […]

As the coronavirus pandemic continues, fewer Canadian benefits plan members are making drug claims, according to Telus Health’s annual drug trends report. The report, based on the drug claims activity of more than 10 million plan members in 2021, found just 56 per cent made a claim in 2021, reflecting a decreased frequency of in-person […]

  • By: Staff
  • June 23, 2022 June 22, 2022
  • 09:00

While medications used for treating inflammatory disease accounted for just 0.7 per cent of claims across Telus Health’s Canadian block of business in 2021, they represent the largest percentage of eligible drug costs at 12.6 per cent, due to the prevalence of high-cost treatments in this drug class. By comparison, diabetes medications accounted for 12 […]

A British Columbia labour arbitration decision is providing insight on how a block level implementation of a benefits provider’s drug cost-control program violated a collective agreement in a unionized workplace. The Douglas College Faculty Association grieved the implementation of Manulife’s DrugWatch program contravened their collective agreement, which ensured “there will be no change to the […]

Copyright_ilixe48_123RF

An announcement regarding long-awaited amendments to the Patented Medicines Review Board regulations was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. PMPRB drug pricing regulations officially coming into effect this July 2. Key stakeholders highlighting value of private payer health care amid plans for […]

  • By: Staff
  • April 22, 2022 April 21, 2022
  • 09:00

After multiple delays, the amendments to the Patented Medicines Review Board regulations will finally come into force on July 1, 2022. Last week, Health Minister Jean-Yves Duclos announced the federal government will proceed with the amendments to provide the PMPRB with new tools to protect Canadians from excessive prices for patented medicines. “This will improve access for […]

  • By: Staff
  • April 19, 2022 April 18, 2022
  • 09:00

This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]